Doxorubicin conjugate

Dreher MR, Raucher D, Balu N et al (2003) Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J Control Release 91 31 3... 

Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R (2005) PEG-doxorubicin conjugates influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 16 775-784... 

MacKay JA, Chen M, McDaniel JR, Liu W, Simnick AJ, Chilkoti A (2009) Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 8 993-999... 

There are numerous reports in the literature of SPE clean-up of a wide variety of analyses prior to chromatographic analysis. Thus, the application of SPE for the preconcentration of the metabolites of peptide-doxorubicin conjugate in human plasma [21], for the... 

R.B. Desai, M.S. Schwartz and B.K. Matuszewski, The identification of three human metabolites of a peptide-doxorubicin conjugate using HLPC-MS-MS in positive and negative ionization modes. J. Chromatogr. Sci. 42 (2004) 317-322. 

Florent J-C, Monneret C (2008) Doxorubicin Conjugates for Selective Delivery to Tumors. 283 99-140... 

Yang, H. M., and Reisfeld, R. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice, Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 1189-1193. 

B16 melanoma, Walker sarcoma, and M5076 forming liver metastasis have been used in the preclinical evaluation of HPMA copolymer-adriamydn conjugates [36]. Other tumors useful for secondary screening are MS-2 sarcoma, NMU-1 murine lung adenocarcinoma, and murine adenocarcinoma Colon 26. These have been used by Zunino et al. [147] to determine the activity of poly (carboxylic acid) immobilized anthracyclines. Mice inoculated intramuscularly with Lewis lung carcinoma have been used by Pratesi et al. [215] to assess the effect of a poly-L-aspartic acid/doxorubicin conjugate. 

Kwon and Kataoka (1995) summarized earlier studies ofthe pharmacokinetics and disposition polyethylene oxid -aspartate)-doxorubicin conjugates (PEGAsp-DOX) (Yokoyama et al.,... 

Jelinkova, M., Strohalm, J., Plocova, D., et al. Targeting of human and mouse T-lym-phocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J. Cont. Rel. 52 253-270, 1998. 

R. Sett, K. Sarkar, and P. K. Das, Macrophage-directed delivery of doxorubicin conjugated to neoglycoprotein using leishmaniasis as the model disease, J. Infect. Dis. 168 994-999 (1993). 

Micellar systems based on amphipathic block-copolymers have gained most attention as intravenously administered drug carrier systems over the years. These block-copolymers are composed of a hydrophilic PEG block and a hydrophobic block based on doxorubicin conjugated poly(aspartic acid) or poly(/i-bcnzyl L-aspartate). 

Over the last several decades, a number of antitumor agents, including chlorambucil, methotrexate, dauno-mycin, and doxorubicin conjugated to tumor specific... 

Sjogren, H.O. Isaksson, M. Willner, D. Hellstrom, I. Flellstrom, K.E. Trail, P.A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 1997, 7, 4530-4536. 

Tolcher, A.W. Sugarman, S. Gelmon, K.A. Cohen, R. Saleh, M. Isaacs, C. Young, L. Healey, D. Onetto, N. Slichenmyer, W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17 (2), 478-484. 

Yoo HS, Lee EA, Park TG (2002) Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 82 17-27... 

Fabulet, O., and Sturtz, G.. Synthesis of gem-bisphosphonic doxorubicin conjugates. Phosphorus, Sulfur Silicon Relat. Elem.. 101, 225, 1995. 

Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. Chem Med Chem. 2006 1 299. 

The first polymer-drug conjugate to be tested in humans for anticancer therapy is doxorubicin coupled with iV-(2-hydroxypropyl)methacrylamide copolymer via a linker that is degraded in lysosomes, thereby releasing the drug [29]. In contrast to the free drug doxorubicin, which has a distribution half-life of 0.08 h and an elimination half-Ufe of 30 h (see Table 8.6), the doxorubicin conjugate has a distribution half-life of 1.8 h and an elimination half-life of 90 h. 

Ohkawa, K., Hatano, T., Yamada, K., Joh, K., et al. (1993) Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53 4238-4242. 

Mitra S, Gaur U, Ghosh P C, et al. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Rel. 74 317-323. 

Shiah J-G, Dvorak M, Kopeckova P, Sun Y, Peterson CM, Kopecek J. Therapeutic efficacy of long-circulating HPMA copolymer-doxorubicin conjugates. Eur J Cancer 2000 37 131-139. 

Cavallo R, Adami M, Magrini R, Colombo G. PK1/PK2 lyophilised formulations. HPMA doxorubicin conjugates with potentially improved antitumour activity. Proceedings of the First World Meeting on APGI/APV, Budapest, 1995 843. 

Pimm M, Perkins AC, Strohalm J, Ulbrich K, Duncan R. Gamma scintigraphy of the biodistribution of I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Target 1996 3 375-383. 

---